Nuwellis Directors Buy Zero‑Cost Options, Signaling Confidence in Patented Catheter Strategy
Insider executives buy zero‑cost options at Nuwellis, signaling confidence in its patented midline catheter and future growth prospects.
2 minutes to read
Nuwellis Inc
Nuwellis Directors Stack Up Free Options as Patent Boom Sparks Insider Optimism—Could a 97% Drop Be Reversed?
Insider option buys at Nuwellis signal optimism about its new midline catheter patent, but investors face low valuation and high volatility—watch the next filings closely.
3 minutes to read